Replies to post #188519 on Biotech Values

[ilpapa]

Thanks for the background. I did take a position, too early at 34.85.
Seems to me that what we have here is not a lethal failure like a trial failure might be, but a botched execution that can be retrieved given time (and money).

[DewDiligence]

[OT]—Update on Dan Vasella, NVS’ first CEO:

http://www.thelocal.ch/20151101/former-novartis-chief-moved-to-monaco-not-the-us